Sale!

Buy Spravato (Esketamine )

Original price was: £250.00.Current price is: £220.00.

The Game-Changer for Treatment-Resistant Depression

Spravato (Esketamine) has transformed the landscape of mental health care, offering hope to adults grappling with treatment-resistant depression. This FDA-approved nasal spray is specially designed for individuals who haven’t responded to traditional antidepressant therapies. With Spravato, you could be on your way to reclaiming control over your mental wellbeing.

How Spravato Works to Improve Mental Health

Unlike conventional antidepressants that target the serotonin system, Spravato focuses on the glutamate system, releasing its unique formula directly to the brain within minutes. This innovative approach helps rapidly restore neural connections that may be impacted by prolonged depression, making it a fast-acting and effective solution for those who need a breakthrough in their treatment journey.

Your Safety, Our Priority

Administered under medical supervision, Spravato is part of a comprehensive treatment program combining the nasal spray with an oral antidepressant. Careful monitoring ensures your safety throughout the process, providing peace of mind every step of the way. Whether you’re stepping into an established clinic or receiving care from a trusted provider, Spravato is delivered in a regulated environment for your wellbeing.

Category: PSYCHEDELIC HUB Tag: Spravato (Esketamine )

Description
Reviews (0)

Spravato (Esketamine )

Buy Spravato (Esketamine ) FDA-Approved Nasal spray

Spravato is indicated for use in adults for the following conditions:

Treatment-Resistant Depression (TRD): For adults who have not responded to at least two different antidepressant treatments in the current depressive episode.24
- 2025 Update: While originally approved only “in conjunction with an oral antidepressant,” newer labeling as of January 2025 allows for its use as monotherapy or in conjunction with an oral antidepressant for TRD.
Major Depressive Disorder with Acute Suicidal Ideation or Behavior (MDSI): To treat depressive symptoms in adults with MDD who are experiencing an acute suicidal crisis.35 (Note: Spravato has not been proven to prevent suicide or reduce suicidal ideation on its own).45

Spravato (Esketamine ) Mechanism of Action

Unlike traditional antidepressants (SSRIs or SNRIs) that target monoamines like serotonin, norepinephrine, or dopamine, Spravato works on the glutamate system:

NMDA Receptor Antagonism: It acts as a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors.6
Neuroplasticity: By blocking these receptors, it is believed to trigger a surge in glutamate, leading to the activation of AMPA receptors. This process promotes “synaptogenesis”—the repair and growth of neural connections in brain regions responsible for mood regulation.

Spravato (Esketamine ) Administration and Dosage

Spravato is never dispensed to a patient for home use; it must be administered in a REMS-certified healthcare setting.189

Form: Disposable nasal spray devices (each containing 28mg).
Induction Phase: Typically 56mg or 84mg administered twice weekly for the first 4 weeks.3
Maintenance Phase: Frequency is usually reduced to once weekly (Weeks 5–8) and then every 1–2 weeks thereafter, depending on the patient’s stability.
Supervision: A healthcare provider must observe the patient self-administer the spray and monitor them for a mandatory 2-hour observation period post-dose.2910
Buy Spravato (Esketamine )